Undisclosed anti-CLDN18.2/anti-CD3 bispecific antibody / Accurus Biosci - LARVOL DELTA

Accurus Biosciences and ImmPACT Bio Enter into an Exclusive Global License Agreement for a Potentially Best-in-Class CLDN18.2 Antibody (Businesswire) - "Accurus Biosciences Inc. ('Accurus') is pleased to announce that it has entered into a worldwide licensing agreement for its CLDN18.2 monoclonal antibody with ImmPACT Bio USA, Inc. ('ImmPACT Bio'), a clinical-stage company focusing on the development of next generation chimeric antigen receptor (CAR) T-cell therapies....Under the terms of the agreement, Accurus Biosciences has granted exclusive worldwide rights to ImmPACT Bio to develop and commercialize next generation cell therapies using a designated antibody from Accurus’ CLDN18.2 antibody portfolio. Accurus retains the rights to develop and commercialize its CLDN18.2 antibody portfolio for all non-cell based therapeutic applications. The financial terms were not disclosed."

Licensing / partnership • Oncology